Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Blood - 22 Aug 2013

Hasan Salma, Lacout Catherine, Marty Caroline, Cuingnet Marie, Solary Eric, Vainchenker William, Villeval Jean-Luc

Abstract excerpt

The acquired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involved in BCR/ABL-negative myeloproliferative neoplasms (MPNs), but its effect on hematopoietic stem cells as a driver of disease emergence has been questioned. Therefore, we reinvestigated the role of endogenous expression of JAK2(V617F) on early steps of hematopoiesis as well as the effect of interferon-α...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Bone Marrow Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Interferon-alpha

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Source

Identifiers

PMID: 23863895
DOI: 10.1182/blood-2013-04-498956

Genes

JAK2
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.PMID 23863895Read ↗

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionalitySemantic proximity Read ↗

Single <i>JAK2</i> -V617F hematopoietic stem cells can initiate MPN in transplantations into non-conditioned recipient miceSemantic proximity Read ↗

IL-1β promotes MPN disease initiation by favoring early clonal expansion of <i>JAK2</i> -mutant hematopoietic stem cellsSemantic proximity Read ↗

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia veraSemantic proximity Read ↗

<i>JAK2</i> <sup>V617F</sup> Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic ClonesSemantic proximity Read ↗

IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2 -mutant hematopoietic stem cellsSemantic proximity Read ↗

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.Semantic proximity Read ↗

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspectiveSemantic proximity Read ↗

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.Semantic proximity Read ↗

Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.Semantic proximity Read ↗

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.Semantic proximity Read ↗

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.